MedTrace Logo

Propranolol for Misophonia

NCT07271485 · Status: RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2025-12-09

No results posted yet for this study

Summary

The primary goal of this study is to investigate whether a one-time dose of 20 mg oral propranolol can temporarily reduce the adverse emotional and physical symptoms triggered by misophonia.

The secondary goals of this study are:

1. Determine potential predictors of response to propranolol treatment, including demographic factors, baseline symptom severity, psychometric instrument item responses, and physiological characteristics.
2. Evaluate the safety and tolerability of propranolol in individuals with misophonia.

Conditions

  • Misophonia
  • Propanolol
  • Misophonia Treatment

Interventions

DRUG

propranolol

A one-time dose of 20 mg propranolol

DRUG

Placebo

A dose of placebo taken orally

Sponsors & Collaborators

  • Bloom Mental Health, LLC

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-12-19
Primary Completion
2026-12-19
Completion
2026-12-19
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07271485 on ClinicalTrials.gov